Ann: TPM Cannabinoid Development Program Update, page-280

Thanks for the summary HT - from the latest Announcement 19/10/20 the highlighted areas outline that this is not going to be a Vitamin OTC enhanced by TPM, there is a very long road in front of them even if they find a partner. (Please note the word Patients rather than Consumers)

****BEGINS******
ASX Limited Market Announcements Office 19 10 2020

TPM® Cannabinoid Development Program Proceeding to Human Clinical Trials
Highlights:

• In vivo studies conducted at Bioneer:FARMA demonstrate significantly increased cannabidiol
(CBD) bioavailability from oral TPM® cannabidiol formulations in rats

• Avecho Biotechnology Limited is now advancing its cannabinoid formulations to human clinical
trials

Melbourne, Australia, 19 October 2020: Avecho Biotechnology Limited (ASX:AVE, “Avecho”, or
“the Company”) today announced that it is proceeding to the next phase of its recently announced
cannabinoid development program – human clinical trials. This decision is supported by positive
results from preliminary in vivo studies which confirmed significantly increased cannabidiol (CBD)
bioavailability from oral TPM® cannabidiol formulations in rats.

Avecho Chief Executive Officer, Dr Paul Gavin, said: “We presented to the market in June, that Avecho
had begun the development of pharmaceutical cannabinoid products combined with our TPM®
technology. These products aim to increase the oral absorption of cannabinoids, overcome the
limitations associated with poor bioavailability and high variability in absorption, and improve the cost
and benefits to patients.”

The development program consists of three main components;
(i) in vitro testing in simulated gastrointestinal digestions,
(ii) animal studies to assess in vivo bioavailability of candidate formulations, and
(iii) subsequent human trials testing the best formulations."
*****ENDS*****